Effect of GM-CSF, G-CSF or Methylprednisolone (MP) on Rituximab-Associated Complement-Mediated Cytotoxicity (CMC) on Non-HodgkinÆs Lymphoma (NHL) Cell Lines.

ASCO SIGN IN

Username:

Create an account

Why Be A Member?

Password:

Remember me

Forgot your username or password?

The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

ASCO Home

Meetings

Abstracts

2001 ASCO Annual Meeting

Effect of GM-CSF, G-CSF or Methylprednisolone (MP) on Rituximab-Associated Complement-Mediated Cytotoxicity (CMC) on Non-HodgkinÆs Lymphoma (NHL) Cell Lines.

Sub-category:

Immunobiology

Category:

Immunobiology and Biologic Therapy

Meeting:

2001 ASCO Annual Meeting

Abstract No:

1095

Citation:

Proc Am Soc Clin Oncol 20: 2001 (abstr 1095)

Author(s):

Francisco J. Hernandez-Ilizaliturri, Elizabeth A. Repasky, Myron S. Czuczman, Roswell Park Cancer Institute, Buffalo, NY.

Abstract:

Rituximab is a chimeric antibody directed against the CD20-antigen found on normal and malignant B-cells. Clinical studies in NHL have demonstrated its efficacy as a single agent or in combination with chemotherapy. Rituximab activity has been associated with CMC, antibody-dependent cellular cytotoxicity and/or induction of apoptosis. GM-CSF and G-CSF have been reported to upregulate CD20 expression in NHL-cell lines. Changes in Rituximab-associated CMC have not been studied in cells pre-treated with GM-CSF/G-CSF. Steroids are part of chemotherapy regimens used against NHL. The effect of steroids on Rituximab activity is uncertain. Objectives: Characterize effects of GM-CSF, G-CSF and MP on Rituximab-associated CMC on NHL cell lines. Material and Methods: 51Cr-labeled Karpas, DHL-4, DHL-10, Ramos and Raji NHL-cells were incubated with GM-CSF, G-CSF or MP prior to treatment with Rituximab at three dose-levels (5mcg/ml, 10mcg/ml and 15mcg/ml) and human complement. 51Cr-release assays were performed and the percentage of lysis was calculated for each cell-line. Differences in CD20 expression were evaluated by flow cytometry. Results: The mean % of 51Cr release was higher in Raji (80.8%+/-0.67), DHL-4 (93.2%+/- 0.6) and Ramos (98.65%+/-1.68) than in DHL-10 (10.7%+/-0.5) or Karpas (20.4%+/-9.6). No differences were noted between the three doses of Rituximab tested. NHL-cells sensitive to Rituximab induced-CMC (Raji, Ramos, and DHL-4) had a higher CD20 expression than those with a lesser degree of CMC-killing (DHL-10 and Karpas). Pre-treatment with G-CSF or GM-CSF did not affect CMC; however, MP significantly reduced Rituximab induced-CMC. Decrease in mean % of lysis in MP pre-treated cells were: Karpas (80%), DHL-10 (79.5%), Ramos (66.7%), DHL-4 (27%) and Raji (13.2%). Conclusions: Pre-treatment of NHL-cells with GM-CSF or G-CSF does not increase CMC. However, pre-treatment with MP is associated with variable reduction in CMC. The sequence of administration of Rituximab with chemotherapy (especially steroids-containing regimens) may impact antibody induced anti-tumor activity.

Associated Presentation(s):

No items found.

Other Abstracts in this Sub-Category:

		1. In Vitro Anti-Melanoma Activity of Apoptosis-Resistant Human gd T Cells. Meeting: 2001 ASCO Annual Meeting Abstract No: 1014 First Author: Klaus A. Hollmig Category: Immunobiology and Biologic Therapy - Immunobiology
		2. Heat Shock Improves Cytotoxic T-Lymphocyte Immune Response to Human Hepatocellular Carcinoma After Co-Culture with Tumor-Lysate Pulsed Dendritic Cells. Meeting: 2001 ASCO Annual Meeting Abstract No: 1016 First Author: Gerd Schueller Category: Immunobiology and Biologic Therapy - Immunobiology
		3. A Phase I Dose-Escalation Study of BIBH 1 in Patients with Advanced or Metastatic Fibroblast Activation Protein Positive Cancer. Meeting: 2001 ASCO Annual Meeting Abstract No: 1028 First Author: Andrew Mark Scott Category: Immunobiology and Biologic Therapy - Immunobiology
		More...

Abstracts by Francisco J. Hernandez-Ilizaliturri:

1. Effect of GM-CSF, G-CSF or Methylprednisolone (MP) on Rituximab-Associated Complement-Mediated Cytotoxicity (CMC) on Non-HodgkinÆs Lymphoma (NHL) Cell Lines.

Meeting: 2001 ASCO Annual Meeting Abstract No: 1095 First Author: Francisco J. Hernandez-Ilizaliturri
Category: Immunobiology and Biologic Therapy - Immunobiology

More...

Presentations by Francisco J. Hernandez-Ilizaliturri:

		1. Strategies to overcoming rituximab-chemotherapy resistance by targeting the autophagy pathway using bortezomib in combination with the Bcl-2 inhibitor obatoclax in non-Hodgkin's lymphomas (NHL). Meeting: 2009 ASCO Annual Meeting Presenter: Francisco J Hernandez-Ilizaliturri, MD Session: Lymphoma and Plasma Cell Disorders (Poster Discussion)
		2. Impaired Ca++ mobilization in rituximab-resistant cells (RRCL) is associated with changes in the structure of CD20 antigen, down-regulation of Bax/Bak pro-apoptotic proteins and up-regulation of the endoplasmic reticulum (ER) Ca++ pump protein SERCA-3. Meeting: 2006 ASCO Annual Meeting Presenter: Francisco J Hernandez-Ilizaliturri, MD Session: Developmental Therapeutics: Immunotherapy (Poster Discussion)
		3. Neutrophil function is necessary for in vivo antitumor activity of rituximab in a severe combined immunodeficiency (SCID) mouse model Meeting: 2002 ASCO Annual Meeting Presenter: Francisco J. Hernandez-Ilizaliturri, MD Session: Tumor Biology/Human Genetics (General Poster Session)
		More...

Educational Book Manuscripts by Francisco J. Hernandez-Ilizaliturri:

No items found.